These results indicated that dysadherin has prometastatic effects that are independent of E-cadherin expression and suggested that CCL2 plays an important role in mediating the prometastatic effect of dysadherin in ER-negative BC [45]. The gene discussed is FXYD5; the disease is breast cancer.